Sugi Predict

Sugi Predict / Targets / STIP1

STIP1

Stress-induced-phosphoprotein 1 · P31948 · STIP1 on Sugi Atlas →

272 patent compounds predicted against STIP1, 228 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8288590 SCHEMBL8288590 0.76 1/20
SCHEMBL7003055 SCHEMBL7003055 0.74 1/20
SCHEMBL5451446 SCHEMBL5451446 0.71 1/20
SCHEMBL5453282 SCHEMBL5453282 0.71 1/20
SCHEMBL7002920 SCHEMBL7002920 0.70 1/20
SCHEMBL5460515 SCHEMBL5460515 0.69 1/20
SCHEMBL8289514 SCHEMBL8289514 0.69 1/20
SCHEMBL13574989 SCHEMBL13574989 0.69 1/20
SCHEMBL8288668 SCHEMBL8288668 0.68 1/20
SCHEMBL8289505 SCHEMBL8289505 0.68 1/20
SCHEMBL11324603 SCHEMBL11324603 0.66 1/20
SCHEMBL26293177 SCHEMBL26293177 0.64 1/20
SCHEMBL5449182 SCHEMBL5449182 0.63 1/20
SCHEMBL26294993 SCHEMBL26294993 0.63 1/20
SCHEMBL1067537 SCHEMBL1067537 0.62 1/20
SCHEMBL8289822 SCHEMBL8289822 0.62 1/20
SCHEMBL7003174 SCHEMBL7003174 0.62 1/20
SCHEMBL8277600 SCHEMBL8277600 0.62 1/20
SCHEMBL1066142 SCHEMBL1066142 0.62 1/20
SCHEMBL23657531 SCHEMBL23657531 0.62 1/20

Clinical trials — most relevant to STIP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit PHASE2/PHASE3WITHDRAWN
Spironolactone on Acute Kidney Injury in Critically Ill Patients PHASE3UNKNOWN
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors PHASE1COMPLETED
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma PHASE1WITHDRAWN
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Quantification of GADD34 Expression in RA nanCOMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma nanCOMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk nanCOMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma nanUNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy nanCOMPLETED
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study nanUNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Acute Passive Heating in Healthy Older Adults nanCOMPLETED
Reduced Ventilator-Free Days and Bacterial Colonization of Sub-Glottic Secretions nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a STIP1 binder may also engage these)

ProteinNameSimilarity
Q3ZBZ8 — 1.000 Q3ZBZ8 →
O54981 — 1.000 O54981 →
O35814 — 1.000 O35814 →
Q4R8N7 — 1.000 Q4R8N7 →
Q60864 — 1.000 Q60864 →
Q7ZWU1 — 0.995 Q7ZWU1 →
Q9USI5 — 0.992 Q9USI5 →
Q5XEP2 — 0.989 Q5XEP2 →
Q8ILC1 — 0.987 Q8ILC1 →
P15705 — 0.987 P15705 →
O16259 — 0.984 O16259 →
Q54DA8 — 0.984 Q54DA8 →
Q43468 — 0.983 Q43468 →
Q9LNB6 — 0.979 Q9LNB6 →
DNAJC7 DnaJ homolog subfamily C member 7 0.978 landscape →
Q9QYI3 — 0.978 Q9QYI3 →
F8RP11 — 0.977 F8RP11 →
Q5R8D8 — 0.976 Q5R8D8 →
Q6WRS2 — 0.974 Q6WRS2 →
Q9STH1 — 0.974 Q9STH1 →
Q23983 — 0.973 Q23983 →
Q4X0I8 — 0.972 Q4X0I8 →
CTR9 RNA polymerase-associated protein CTR9 homolog 0.972 landscape →
Q9SRS9 — 0.971 Q9SRS9 →
Q54HL6 — 0.971 Q54HL6 →
Q20683 — 0.971 Q20683 →
P10591 — 0.971 P10591 →
Q5M7J9 — 0.970 Q5M7J9 →
Q4QR29 — 0.970 Q4QR29 →
Q62018 — 0.970 Q62018 →